Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG1MA3 With and Without AdMA3 in Advanced MAGE-A3-Expressing Solid Tumours
NCT02285816Phase 2Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jan 2015
- Primary completion
- Sep 2019
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of mg1-magea3 in solid tumor (3 arms), sponsored by Canadian Cancer Trials Group. Primary endpoints: Toxicity as measured by adverse events at 3 years and Objective tumour response rate at 16 weeks. Started Jan 2015; status: active, not recruiting.
02
Drugs
mg1-magea3
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02285816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02285816.